신종감염병과 혈액제제 안전 = Emerging Infectious Disease and Safety of Blood Components

다국어 초록 (Multilingual Abstract)

Recently, the emergency of Middle East Respiratory Syndrome in Korea raised public concern regarding emerging infectious disease (EID) and affected the strategy for blood safety. Although some cases of EID such as West Nile virus in the United States and hepatitis E virus in Japan emerged in a restricted area, the emergence can rapidly affect the situation in other countries in a globalized society with advancements in transportation and international exchange. Because the risk of transfusion-mediated infection may occur by the agent of EID which can be transmitted through blood, the strategy for safety must be considered for agents that were not tested in the stage of blood donor screening. We reviewed the characteristics of transfusion-transmissible EIDs raising concerns worldwide and the strategies which had been adopted.

국문 초록 (Abstract)

최근 국내에서 유행하였던 중동호흡기증후군으로 신종감염병에 대한 경각심이 다시 커지고, 이는 혈액에 대한 안전성 강화 정책에도 영향을미치게 되었다. 미국에서의 West Nile Virus 감염, 일본에서의 E형간염 등 특정 국가에서 제한적으로 유행하는 경우도 있으나, 국가간 교통수단의발달과 교류가 활발한 현재상황에서는 특정 감염병의 발생은 그 나라에 국한되지 않고 전세계적으로 영향을 끼칠 수 있게 되었다. 혈액을 매개로하는 신종감염병의 발생은 수혈안전성에 대한 우려를 증폭시키고, 헌혈자에 대한 선별검사를 실시하지 못하는 경우에 대체할 수 있는 혈액제제의 안전성 확보방안이 고려되어야 한다. 본 연구자들은 그 동안 국내외적으로 유행하고 이슈화되었던 수혈 매개 가능 신종감염병에 대하여 자료를 통한 특성을 살펴보고 혈액제제의 안전을 위하여 취해진 국외 및 국내 대안을 정리해 보았다.

참고문헌 (Reference)

• 1 World Health Organization, "WHO recommendations on SARS and blood safety. Emergencies preparedness, response"
• 2 American Association of Blood Bank, "Variant Creutzfeldt–Jakob Disease (vCJD). emerging infectious disease agents and their potential threat to transfusion safety"
• 3 National Blood Service, "Variant CJD and blood donation"
• 4 US FDA, "Use of nucleic acid tests to reduce the risk of transmission of West Nile virus from donors of whole blood and blood components intended for transfusion"
• 5 Pealer LN, "Transmission of West Nile virus through blood transfusion in the United States in 2002" 349 : 1236-1245, 2003
• 6 Cho YH, "Transfusion-transmitted Malaria in Korea - 10cases during 1997~2001" 12 : 263-270, 2001
• 7 Reesink HW, "The use of malaria antibody tests in the prevention of transfusion-transmitted malaria" 98 : 468-478, 2010
• 8 Bhatt S, "The global distribution and burden of dengue" 496 : 504-507, 2013
• 9 Korean Red Cross Blood Services Headquarter, "Strategy for the safety related with new influenza. Blood information"
• 10 Ministry of Health, Labor and Welfare, "Strategy for the chagas disease" Labor and Welfare
• 11 Ministry of Health, Labor and Welfare, "Strategy for the blood donor in the occurrence of West Nile Virus infection in Japan" Labor and Welfare
• 12 US FDA, "Recommendations for blood establishments:training of back-up personnel, assessment of blood donor suitability and reporting certain changes to an approved application"
• 13 Sobata R, "No viremia of pandemic (H1N1) 2009 was demonstrated in blood donors who had donated blood during the probable incubation period" 51 (51): 949-956, 2011
• 14 Ministry of Health, "Labor and Welfare. Strategy for the variant Creutzfeldt-Jakob disease"
• 15 World Health Organization, "Influenza update. Influenza"
• 16 Korean Center for Disease Control and Prevention, "Infectious disease statistics system"
• 17 US FDA, "Guidance for industry: use of serological tests to reduce the risk of transmission of Trypanosoma cruzi infection in whole blood and blood components intended for transfusion"
• 18 US FDA, "Guidance for industry: revised recommendations for the assessment of donor suitability and blood product safety in cases of Suspected Severe Acute Respiratory Syndrome (SARS) or exposure to SARS"
• 19 US FDA, "Guidance for industry: revised preventive measures to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood products"
• 20 US FDA, "Guidance for industry: recommendations for donor questioning, deferral, reentry and product management to reduce the risk of transfusion-transmitted Malaria"
• 21 Japanese Red Cross Society, "Finalization of the blood donation refrain related with the occurrence of the Dengue virus infection. Website of Japanese Red Cross Society"
• 22 American Association of Blood Bank, "Fact sheets created or updated post publication of the TRANSFUSION August 2009 supplement. Emerging infectious disease agents and their potential threat to transfusion safety"
• 23 Atreya C, "FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety" 51 (51): 855-871, 2011
• 24 American Association of Blood Bank, "Emerging infectious disease agents and their potential threat to transfusion safety"
• 25 American Association of Blood Bank, "Emerging infectious disease agents and their potential threat to transfusion safety"
• 26 Stramer SL, "Emerging infectious disease agents and their potential threat to transfusion safety" 49 (49): 1-29, 2009
• 27 Japanese Red Cross Society, "Cases of blood donation refrain"
• 28 Korean Red Cross Blood Transfusion Research Institute, "Blood transfusion safety: review and recommendations on possible safety measures – Focus on transfusion-transmittable agnets" Seoul: Korean Health Promotion Foundation 2007
• 29 US FDA, "Blood products advisory committee meeting on strategies for implementation of antibody and nucleic acid-based testing for Babesia microti in blood donors"